Fulvestrant plus capivasertib for metastatic breast cancer

Affiliations

Comment

Tim Johannes Adrianus Dekker. Lancet Oncol. 2020 May.

. 2020 May;21(5):e232.

doi: 10.1016/S1470-2045(20)30153-4.

¹ Department of Internal Medicine, Haaglanden Medisch Centrum, The Hague 2512 VA, Netherlands. Electronic address: t.j.a.dekker@gmail.com.

No abstract available

Comment in

Fulvestrant plus capivasertib for metastatic breast cancer.
Ludmir EB, McCaw ZR, Kim DH, Tian L, Wei LJ. Ludmir EB, et al. Lancet Oncol. 2020 May;21(5):e233. doi: 10.1016/S1470-2045(20)30228-X. Lancet Oncol. 2020. PMID: 32359498 No abstract available.
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
Jones RH, Casbard A, Carucci M, Foxley A, Howell SJ. Jones RH, et al. Lancet Oncol. 2020 May;21(5):e234. doi: 10.1016/S1470-2045(20)30237-0. Lancet Oncol. 2020. PMID: 32359499 No abstract available.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.